Generic Drugs Market - Global Industry Analysis, Market Size, Share, Growth, Trends, Region Outlook, And Segment Forecasts, 2022 - 2030

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Drugs Market

5.1. Covid-19: generic drugs Industry Impact
5.2. generic drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The low cost of generics, as an alternative to branded drugs
6.1.1.2. Large number of patent expired branded drugs
6.1.1.3. Initiatives by governments and other regulatory bodies
6.1.2. Market Restraints
6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs
6.1.3. Market Opportunities
6.1.3.1. Use of RPA to ensure regulatory and standards compliance

Chapter 7. Global Generic Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic drugs Market Revenue by Market Players (2017 - 2020)
7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 - 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. generic drugs Market, by Drug Type, 2017-2027
8.1.1. Simple Generics
8.1.1.1. Market Revenue and Forecast (2017-2027)
8.1.2. Super Generics
8.1.2.1. Market Revenue and Forecast (2017-2027)

Chapter 9. Global Generic Drugs Market, By Brand

9.1. generic drugs Market, by Brand, 2017-2027
9.1.1. Pure generic drugs
9.1.1.1. Market Revenue and Forecast (2017-2027)
9.1.2. Branded generic drugs
9.1.2.1. Market Revenue and Forecast (2017-2027)

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration

10.1. generic drugs Market, by Route of Drug Administration, 2017-2027
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2027)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2017-2027)
10.1.3. Parental
10.1.3.1. Market Revenue and Forecast (2017-2027)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2027)

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. generic drugs Market, by Therapeutic Application, 2017-2027
11.1.1. Central nervous system (CNS)
11.1.1.1. Market Revenue and Forecast (2017-2027)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2017-2027)
11.1.3. Dermatology
11.1.3.1. Market Revenue and Forecast (2017-2027)
11.1.4. Oncology
11.1.4.1. Market Revenue and Forecast (2017-2027)
11.1.5. Respiratory
11.1.5.1. Market Revenue and Forecast (2017-2027)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2027)

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. generic drugs Market, by Distribution Channel, 2017-2027
12.1.1. Hospitals Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2027)
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2027)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2027)

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Drug Type(2017-2027)
13.1.2. Market Revenue Forecast by Brand (2017-2027)
13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.1.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2027)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2027)
13.2. Europe
13.2.1. Market Revenue Forecast by Drug Type (2017-2027)
13.2.2. Market Revenue Forecast by Brand (2017-2027)
13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.2.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2027)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2027)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2027)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2027)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Drug Type (2017-2027)
13.3.2. Market Revenue Forecast by Brand (2017-2027)
13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.3.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2027)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2027)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2027)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2027)
13.4. LATAM
13.4.1. Market Revenue Forecast by Drug Type (2017-2027)
13.4.2. Market Revenue Forecast by Brand (2017-2027)
13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.4.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2027)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2027)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Drug Type (2017-2027)
13.5.2. Market Revenue Forecast by Brand (2017-2027)
13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.5.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2027)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2027)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2027)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2027)

Chapter 14. Company Profiles

14.1. Abbott Laboratories
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Application
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. Teva Pharmaceutical Industries Ltd.
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Application
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. ALLERGAN
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Application
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Sandoz International GmbH
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Application
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Mylan N.V.
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Application
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. STADA Arzneimittel AG
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Application
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Baxter International Inc.
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Application
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Eli Lilly and Company
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Application
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. GlaxoSmithKline Plc.
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Application
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies
14.10. Pfizer Inc.
14.10.1. Company Overview, Business Information, Regional Presence
14.10.2. Product Portfolio Analysis
14.10.2.1. Product Details, Specification, Application
14.10.3. Revenue, Price, and Gross Margin (2017-2020)
14.10.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms